We welcome this contribution to the growing body of evidence demonstrating the safety
of active surveillance (AS) for biopsy-proven renal oncocytomas. The low median growth
rate of 2.4 mm/y reported in this work is in keeping with our own series
1
and that of others,
- Neves JB
- Varley R
- Agnesi S
- et al.
Growth and renal function dynamics of renal oncocytomas in patients on active surveillance.
BJU Int. Published online 2021; https://doi.org/10.1111/bju.15499
2
,3
in which no patient has developed metastases or disease-related mortality during
median follow up of 29-34 months.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to UrologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Growth and renal function dynamics of renal oncocytomas in patients on active surveillance.BJU Int. Published online 2021; https://doi.org/10.1111/bju.15499
- Active surveillance is suitable for intermediate term follow-up of renal oncocytoma diagnosed by percutaneous core biopsy.BJU Int. 2016; 118: 30-34https://doi.org/10.1111/bju.13538
- Active surveillance for renal neoplasms with oncocytic features is safe.J Urol. 2016; 195: 581-587https://doi.org/10.1016/j.juro.2015.09.067
- Renal oncocytoma: landscape of diagnosis and management.BJU Int. Published online 2021; https://doi.org/10.1111/bju.15496
- Outcomes of active surveillance for young patients with small renal masses: prospective data from the DISSRM registry.J Urol. 2021; 205: 1286-1293https://doi.org/10.1097/ju.0000000000001575
Article info
Publication history
Published online: October 23, 2021
Accepted:
September 14,
2021
Received:
September 13,
2021
Footnotes
Re: Deledalle et al. Active Surveillance for Biopsy Proven Renal Oncocytomas: Outcomes and Feasibility. Urology 2021.
Funding Support: HW receives funding from The Urology Foundation
Identification
Copyright
© 2021 Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Author Reply to Letter to the EditorUrologyVol. 159
- PreviewWe thank Kokayi et al for their interest in our study on the feasibility and outcomes of active surveillance (AS) in renal oncocytoma recently published in Urology.1 We also read with great interest their results on the growth and renal function dynamics of renal oncocytomas in patients on AS.2 It is a great satisfaction to see that our institutions share common research topics in addition to similar conclusions.
- Full-Text
- Preview
